Palisade Bio Initiates Phase 3 Study of LB1148 in Lead Indication for Postoperative Return of Bowel Function Completion of enrollment for Phase 3 study targeted within 18-24 months In multiple clinical studies, LB1148 has demonstrated statistically significant acceleration in the time to the return of...

Palisade Bio Reports First Quarter 2022 Financial Results and Provides Corporate Update Phase 3 study of LB1148 in lead indication for postoperative return of bowel function on track to commence Q2 2022 Ongoing Phase 2 study of LB1148 for the prevention of post-surgical abdominal...

Palisade Bio Announces Inducement Awards Under Inducement Plan for Key New Hires CARLSBAD, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical-stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal complications,...